Expert committee on novel DPP-4 inhibitor TRADJENTA (linagliptin) in treatment of type 2 diabetes mellitus

Expert committee on novel DPP-4 inhibitor TRADJENTA (linagliptin) in treatment of type 2 diabetes mellitus

В Москве 11 апреля 2012 г. состоялость заседание экспертного совета по применению нового ингибитора дипептидилпептидазы-4 (ДПП-4) ТРАЖЕНТА (линаглиптин) в лечении сахарного диабета 2 типа (СД2). Планируется, что препарат уже осенью станет доступен для пациентов....

Full description

Bibliographic Details
Main Author:	Editorial team Diabetes Mellitus
Format:	Article
Language:	English
Published:	Endocrinology Research Centre 2012-06-01
Series:	Сахарный диабет
Subjects:	diabetes mellitus dpp-4 inhibitors linagliptin
Online Access:	https://www.dia-endojournals.ru/jour/article/view/5527

Similar Items

Russian Association of Endocrinologists reports commencement of Trajenta clinical use
by: Editorial team Diabetes Mellitus
Published: (2012-12-01)

A Localized Painful Rash Induced by Linagliptin in a Patient with type 2 Diabetes
by: İsmail Yıldız, et al.
Published: (2019-05-01)

Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme
by: Johansen Odd, et al.
Published: (2012-01-01)

Expert committee on introduction of incretin-based therapy in Russia: advance and failure
by: Editorial team Diabetes Mellitus
Published: (2012-09-01)

A Randomized Clinical Trial of Linagliptin vs. Standard of Care in Patients Hospitalized With Diabetes and COVID-19
by: Ran Abuhasira, et al.
Published: (2021-12-01)

New prospects in the treatment of diabetes mellitus
by: Minara Shamkhalovna Shamkhalova, et al.
Published: (2012-12-01)

The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Directly Enhances the Contractile Recovery of Mouse Hearts at a Concentration Equivalent to that Achieved with Standard Dosing in Humans
by: Sri Nagarjun Batchu, et al.
Published: (2020-08-01)

Linagliptin in Combination With Metformin Ameliorates Diabetic Osteoporosis Through Modulating BMP-2 and Sclerostin in the High-Fat Diet Fed C57BL/6 Mice
by: Nikita Nirwan, et al.
Published: (2022-07-01)

National Council of Experts: the place of DPP-4 inhibitors in the treatment of patients with type 2 diabetes mellitus
by: M. V. Shestakova, et al.
Published: (2023-12-01)

Efficacious and safe management of type 2 diabetes mellitus using DPP-4 inhibitors
by: Alexander Sergeevich Ametov, et al.
Published: (2010-06-01)

Alternate-day dosing of linagliptin in type 2 diabetes patients controlled on once daily dose: A case series
by: Manash P Baruah, et al.
Published: (2016-01-01)

Linagliptin and cardiovascular outcomes in type 2 diabetes after acute coronary syndrome or acute ischemic stroke
by: Yan-Rong Li, et al.
Published: (2018-01-01)

Effects of linagliptin on endothelial function and postprandial lipids in coronary artery disease patients with early diabetes: a randomized, placebo-controlled, double-blind trial
by: Norbert J. Tripolt, et al.
Published: (2018-05-01)

Linagliptin Attenuates the Cardiac Dysfunction Associated With Experimental Sepsis in Mice With Pre-existing Type 2 Diabetes by Inhibiting NF-κB
by: Sura Al Zoubi, et al.
Published: (2018-12-01)

Palpable Purpura in a Patient with Uncontrolled Type 2 Diabetes Mellitus: Possible Side Effect of Linagliptin
by: Ömercan Topaloğlu, et al.
Published: (2019-03-01)

Effect of Switching from Linagliptin to Teneligliptin Dipeptidyl Peptidase-4 Inhibitors in Older Patients with Type 2 Diabetes Mellitus
by: Han E, et al.
Published: (2020-11-01)

The effect of DPP-4 inhibition to improve functional outcome after stroke is mediated by the SDF-1α/CXCR4 pathway
by: Fausto Chiazza, et al.
Published: (2018-05-01)

Is the combination of linagliptin and allopurinol better prophylaxis against post-contrast acute kidney injury? A multicenter prospective randomized controlled study
by: Ahmed Fayed, et al.
Published: (2023-12-01)

Establishment of a selective evaluation method for DPP4 inhibitors based on recombinant human DPP8 and DPP9 proteins
by: Jinglong Liu, et al.
Published: (2014-04-01)

Plasma Nitrate Levels Are Related to Metabolic Syndrome and Are Not Altered by Treatment with DPP-4 Inhibitor Linagliptin: A Randomised, Placebo-Controlled Trial in Patients with Early Type 2 Diabetes Mellitus
by: Melanie Reijrink, et al.
Published: (2021-09-01)

DPP4 in Diabetes
by: Diana eRöhrborn, et al.
Published: (2015-07-01)

Post-marketing Study of Linagliptin: A Pilot Study
by: Gabrielle Kéfrem Alves Gomes, et al.
Published: (2019-05-01)

SGLT2 Inhibitor Empagliflozin and DPP4 Inhibitor Linagliptin Reactivate Glomerular Autophagy in <i>db/db</i> Mice, a Model of Type 2 Diabetes
by: Anton I. Korbut, et al.
Published: (2020-04-01)

Comparison of adherence and persistence among adults with type 2 diabetes mellitus initiating saxagliptin or linagliptin
by: Farr AM, et al.
Published: (2016-08-01)

Linagliptin use in older individuals with type 2 diabetes
by: Pratley RE
Published: (2014-07-01)

The Effect of DPP-4 Inhibitors on Metabolic Parameters in Patients with Type 2 Diabetes
by: Eun Yeong Choe, et al.
Published: (2014-06-01)

The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Ameliorates Endothelial Inflammation and Microvascular Thrombosis in a Sepsis Mouse Model
by: Shen-Chih Wang, et al.
Published: (2022-03-01)

Acute and Chronic Exposure to Linagliptin, a Selective Inhibitor of Dipeptidyl Peptidase-4 (DPP-4), Has an Effect on Dopamine, Serotonin and Noradrenaline Level in the Striatum and Hippocampus of Rats
by: Małgorzata Łupina, et al.
Published: (2024-03-01)

Renoprotective Effects of DPP-4 Inhibitors
by: Daiji Kawanami, et al.
Published: (2021-02-01)

Experience with sitagliptin (the first DPP-4 inhibitor) application to the treatment of type 2 diabetes mellitus in the Russian Federation:Results of the DIA-DA observation program
by: Marina Vladimirovna Shestakova
Published: (2010-09-01)

Evaluation of efficacy and safety of DPP-4 inhibitors for Chinese elderly patients with type 2 diabetes mellitus
by: Dong-Ni Yu, et al.
Published: (2020-04-01)

Meeting of the expert committee on the use of pre-mixed insulin preparation Humalog Mix 50 in type 2 diabetes mellitus
by: Editorial team Diabetes Mellitus
Published: (2013-12-01)

Dipeptidyl Peptidase-4 Inhibitors for the Potential Treatment of Brain Disorders; A Mini-Review With Special Focus on Linagliptin and Stroke
by: Vladimer Darsalia, et al.
Published: (2019-05-01)

Green quantitative methods for linagliptin and empagliflozin in dosage forms
by: Fraihat Safwan M.
Published: (2024-04-01)

Micro-Environmental Signature of The Interactions between Druggable Target Protein, Dipeptidyl Peptidase-IV, and Anti-Diabetic Drugs
by: Chiranjib Chakraborty, et al.
Published: (2017-01-01)

Role of DPP-4 and SGLT2 Inhibitors Connected to Alzheimer Disease in Type 2 Diabetes Mellitus
by: A Young Sim, et al.
Published: (2021-08-01)

Preferential prescribing of linagliptin in type 2 diabetes patients in an expanded post‐marketing surveillance study in Japan
by: Soulmaz Fazeli Farsani, et al.
Published: (2019-09-01)

The new drug saxagliptin is now registrated in Russia
by: Editorial team Diabetes Mellitus
Published: (2010-12-01)

Linagliptin in the frail elderly diabetic patient
by: Eva Palmieri
Published: (2018-09-01)

Urate-lowering effects of dipeptidyl peptidase-4 inhibitors
by: Taras S. Panevin, et al.
Published: (2020-12-01)